Pharmamarketeer
onderzoek

Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS

15 oktober 2018
InPharm.com

Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in the treatment of relapsing and primary progressive forms of multiple sclerosis (MS), showing a wide range of benefits over other therapies at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)